The trial aims to measure AF burden—the percentage of time patients spend in arrhythmia—as its primary efficacy endpoint
Private financing round supported by Fidelity Management & Research Company, T. Rowe Price and Durable Capital Partners
As an initial remote monitoring diagnostic approach, Philips BioTel Heart MCOT detected 4.6 times more patients with atrial fibrillation compared to implantable loop recorder alone
71-year-old high-risk patient with atrial fibrillation and ventricular tachycardia discharged next day
The SCOUT-HCM trial hit its primary endpoint, showing a clinically meaningful and statistically significant reduction in Valsalva left ventricular outflow tract
CIRRUS-HCM, an open-label, multi-part study, evaluates EDG-7500 in patients with obstructive and nonobstructive HCM
AFib is a progressive condition where timely intervention is critical to disease management and, ultimately, the patient's quality of life
TactiFlex, the world’s first catheter with a flexible tip and contact?force sensing, allows doctors to deliver energy precisely and safely.
The pharma company will donate more than seven tons of its active pharmaceutical ingredient (API) to bolster the American supply chain
The company has unveiled the results of pirtobrutinib from its BRUIN CLL-313 study
Subscribe To Our Newsletter & Stay Updated
